In Brief for January 25, 2023

In Brief for Feb. 8, 2023

Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says

Pragmatic Approach to Trial Design Born from Lung-MAP Substudy

In Brief for April 26, 2023

In Brief for May 24, 2023

In Brief for June 28, 2023

US Approves Osimertinib with Chemotherapy for EGFR+ NSCLC; Approvals Pending in Other Countries

US FDA Approves Frontline Amivantamab Combination for Patients with EGFR exon 20 Insertion-mutated NSCLC

Regulating Artificial Intelligence

US FDA Grants Breakthrough Therapy Designation for Novel TKI Targeting HER2, EGFR

US Food and Drug Administration Accepts New Drug Application for Ensartinib